Fig. 1. Lung TRACERx patient-derived xenograft (PDX) cohort overview.

A Schematic of the study protocol to derive and expand PDX models within the lung TRACERx study. B Outcomes of regional non-small cell lung cancer (NSCLC) tumor tissue engraftment in NSG mice, including patient characteristics. C Downsampling to one engraftment attempt for each patient. Green line indicates median modeled number of patients with a PDX model following a single engraftment attempt, brown dashed line indicates the observed number of patients for whom PDX models were derived with a multi-region sampling approach. D Time from tumor injection to PDX harvest by passage number. Only PDX models for which complete P0-P3 data were available are shown (n = 40 PDX models at each passage). Bar shows median time for all models. Two-sided Friedman test with Dunn’s test for multiple comparisons, p values as indicated. E Disease-free survival over a 1600 day period following tumor resection is shown grouped by the generation (PDX) or not (no PDX) of at least one regional NSCLC PDX model for each patient. Log rank test, p value as indicated. LUAD—lung adenocarcinoma; LUSC—lung squamous cell carcinoma; SCLC—small cell lung cancer; LCNEC—large cell neuroendocrine carcinoma.